By Nana O 
Researchers at Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have unveiled groundbreaking findings that redefine the understanding of glioblastoma, the most aggressive and lethal form of brain cancer. Previously considered a disease confined to brain tissue, new research indicates that glioblastoma actively engages with and damages the skull bone, profoundly altering the immune cell composition within the skull’s marrow and disrupting the body’s broader immune system. This paradigm-shifting discovery, published on October 3 in the prestigious journal Nature Neuroscience, suggests that current therapeutic strategies, which treat glioblastoma as a localized ailment, may be insufficient and could even be inadvertently counterproductive.
The implications of this research are far-reaching, potentially explaining the dismal survival rates associated with glioblastoma and opening new avenues for therapeutic intervention. "Our discovery that this notoriously hard-to-treat brain cancer interacts with the body’s immune system may help explain why current therapies — all of them dealing with glioblastoma as a local disease — have failed, and it will hopefully lead to better treatment strategies," stated Jinan Behnan, Ph.D., the paper’s corresponding author. Dr. Behnan, an assistant professor in the Leo M. Davidoff Department of Neurological Surgery and in the department of microbiology & immunology at Einstein, and a member of the National Cancer Institute (NCI)-designated MECCC, highlighted the critical need to re-evaluate the systemic nature of glioblastoma.
Glioblastoma remains a formidable challenge in oncology. In the United States, approximately 15,000 individuals are diagnosed with this devastating cancer each year, according to the NCI. Despite aggressive treatment regimens, which typically involve a combination of surgery, radiation therapy, and chemotherapy, the median survival time for patients remains tragically short, often around 15 months. This new research offers a glimmer of hope by suggesting that targeting the intricate interplay between glioblastoma, skull bone, and the immune system could lead to more effective treatments.
A Matter of Marrow: Unraveling the Skull’s Role
The skull, like other bones in the human body, houses bone marrow. This vital tissue is the birthplace of various blood cells, crucially including those that form the immune system. Recent scientific advancements have illuminated the existence of incredibly fine channels that directly connect the skull to the brain, facilitating a continuous exchange of molecules and immune cells. It was this newly understood anatomical connection that inspired Dr. Behnan’s team.
Employing sophisticated imaging technologies, the researchers meticulously examined mice that had developed two distinct types of glioblastoma. Their observations revealed a striking pattern: the tumors actively induced erosion of the skull bones, with the most significant damage occurring along the sutures, the fibrous joints where skull bones fuse. Crucially, this type of bone loss appeared to be a specific consequence of glioblastoma and other aggressive brain tumors. Mice experiencing strokes, other forms of brain injury, or cancers located elsewhere in the body did not exhibit this particular bone degradation. To corroborate their findings in humans, the researchers analyzed CT scans of patients diagnosed with glioblastoma. These scans mirrored the observations in mice, revealing a reduction in skull thickness in the same cranial regions where bone erosion was identified in the animal models.
The erosion of skull bone, as observed in the mice, had a significant impact on the connectivity between the skull and the brain. The researchers found that this bone loss led to an increase in both the number and the size of the channels linking the skull and the brain. This structural alteration led the scientists to hypothesize that these enlarged channels could serve as conduits for the tumor to transmit molecular signals into the skull marrow. These signals, they proposed, could then alter the immune environment within the marrow, potentially fostering tumor growth and progression.
A Tilt Toward Inflammation: Immune System Hijacked
To understand the precise impact of glioblastoma on the skull marrow’s immune landscape, the researchers utilized single-cell RNA sequencing, a cutting-edge technique that allows for the analysis of gene expression in individual cells. The results were profound. Glioblastoma had drastically shifted the balance of immune cells within the skull marrow, heavily favoring pro-inflammatory myeloid cells. Specifically, the levels of inflammatory neutrophils nearly doubled, while several types of antibody-producing B cells and other B cell populations were dramatically reduced, almost to the point of elimination.
This dramatic skewing of the immune environment has critical implications for glioblastoma’s aggressiveness. "The skull-to-brain channels allow an influx of these numerous pro-inflammatory cells from the skull marrow to the tumor, rendering the glioblastoma increasingly aggressive and, all too often, untreatable," explained E. Richard Stanley, Ph.D., a co-author of the study and professor of developmental and molecular biology at Einstein. Dr. Stanley emphasized that this discovery underscores the urgent need for therapeutic strategies that can restore the normal equilibrium of immune cells within the skull marrow of glioblastoma patients. He suggested that a promising approach would involve suppressing the production of pro-inflammatory neutrophils and monocytes while simultaneously promoting the generation of beneficial T and B cells.
The research further illuminated the systemic nature of glioblastoma by comparing the immune responses in the skull marrow and the femur marrow. While glioblastoma activated specific genes in the skull marrow that amplified the production of inflammatory immune cells, the cancer had the opposite effect on the femur marrow. In the femur, glioblastoma suppressed genes essential for the production of several crucial types of immune cells. This differential response highlights that glioblastoma is not a localized disease but rather one that exerts a widespread influence on the body’s immune system through various mechanisms.
Unintended Consequences of Bone-Saving Drugs
Intrigued by the observed bone erosion and its connection to the immune system, the researchers explored the potential effects of anti-osteoporosis medications. These drugs are designed to prevent bone loss, and the scientists hypothesized they might influence skull-bone erosion, glioblastoma progression, or both. To test this, they administered two FDA-approved osteoporosis drugs, zoledronic acid and denosumab, to mice bearing glioblastoma tumors.
Both drugs successfully halted the skull erosion, a significant finding in itself. However, the outcomes for tumor progression were more complex. In one type of glioblastoma model, zoledronic acid not only prevented bone loss but also appeared to accelerate tumor growth. Furthermore, both zoledronic acid and denosumab demonstrated an unexpected negative interaction with anti-PD-L1, a type of immunotherapy drug that enhances the activity of tumor-fighting T cells. The administration of these osteoporosis drugs blocked the beneficial effects of anti-PD-L1 therapy, suggesting a potential contraindication for combining these treatments in certain glioblastoma patients.
This finding raises critical questions about the management of glioblastoma patients who may also have or develop bone-related conditions. It suggests a need for careful consideration and personalized treatment approaches when managing co-morbidities in the context of aggressive cancer.
Broader Implications and Future Directions
The findings presented in Nature Neuroscience represent a significant departure from conventional understanding and open up a new frontier in glioblastoma research. The study, titled "Brain Tumors Induce Widespread Disruption of Calvarial Bone and Alteration of Skull Marrow Immune Landscape," involved a multidisciplinary team of researchers from MECCC, Einstein, and international institutions including Osaka University (Japan), Karolinska Hospital (Sweden), Duke University Medical Center (USA), University of California, San Francisco (USA), and the German Rheumatism Research Center (Germany).
The implications of this research are profound for several reasons:
- Rethinking Glioblastoma as a Systemic Disease: The discovery that glioblastoma actively remodels bone and manipulates the immune system within the skull marrow compels a re-evaluation of glioblastoma as a purely local brain tumor. This systemic perspective could lead to the development of therapies that target not only the tumor itself but also its broader impact on the body.
- Novel Therapeutic Targets: The identified alterations in skull marrow immune cell composition, particularly the dominance of pro-inflammatory myeloid cells and the depletion of B cells, present potential new targets for drug development. Strategies aimed at rebalancing these immune populations could be a key to overcoming treatment resistance.
- Understanding Treatment Failure: The research offers a plausible explanation for the limited success of current glioblastoma therapies. By understanding how the tumor manipulates its microenvironment and the immune system, researchers can develop more effective and targeted treatments.
- Impact on Bone-Targeting Therapies: The findings regarding osteoporosis drugs highlight the complexity of treating patients with multiple conditions. It underscores the necessity of comprehensive preclinical testing to assess potential drug interactions and unintended consequences, especially when dealing with aggressive diseases like glioblastoma.
The path forward involves translating these preclinical findings into clinical applications. Future research will likely focus on:
- Developing Drugs to Restore Immune Balance: The identification of specific immune cell populations that are dysregulated in the skull marrow provides a clear target for therapeutic intervention. The development of drugs that can selectively suppress pro-inflammatory cells and boost anti-tumor immune responses is a high priority.
- Investigating Systemic Immune Modulation: Given that glioblastoma appears to have systemic effects, strategies that modulate the broader immune system in conjunction with local tumor treatment could be beneficial.
- Personalized Treatment Strategies: Understanding the individual variations in how glioblastoma affects bone and immune systems could lead to more personalized treatment plans tailored to each patient’s unique disease profile.
- Early Detection and Monitoring: The research may also inform the development of new diagnostic tools or biomarkers that can detect or monitor the systemic effects of glioblastoma, potentially leading to earlier intervention.
The collaboration between Montefiore Einstein Comprehensive Cancer Center and Albert Einstein College of Medicine has once again pushed the boundaries of scientific understanding. This latest discovery about glioblastoma’s intricate relationship with the skull and immune system offers a critical new perspective, igniting hope for the development of more effective treatments for one of the most devastating cancers known to humankind. The scientific community will be closely watching as these findings pave the way for a new era of glioblastoma research and patient care.
